Effect of Insulin Detemir (Levemir®) on Risk of Hypoglycaemia and Glycaemic Parameters: Experience from Real Life Practice in Indonesian Patients with Diabetes Mellitus

Autor: Pradana Soewondo, Anand Jain

Publikováno v: Journal of the ASEAN Federation of Endocrine Societies, Vol 26, Iss 1 (2024)

Objective. To evaluate the safety and efficacy of insulin detemir in patients with diabetes mellitus in Indonesia. Methods. This was a multi-centre, prospective, 12-week observational study in patients with diabetes mellitus conducted in Indonesia.

Externí odkaz: https://doaj.org/article/f9be2c1d1ffd420d8f045eaf689c33a2

Segurança dos análogos de insulina glargina versus detemir em pacientes com Diabetes tipo 1 – revisão sistemática e metanálise

Autor: Thales Brendon Castano Silva, Marina Morgado Garcia, Paulo Henrique Ribeiro Fernandes Almeida, Vânia Eloisa Araújo, Francisco De Assis Acúrcio, Augusto Afonso Guerra Junior, Juliana Álvares

Publikováno v: Jornal de Assistência Farmacêutica e Farmacoeconomia, Vol 2, Iss s.1 (2024)

Introdução: O diabetes mellitus tipo 1 (DM1) é uma doença crônica caracterizada pela destruição parcial ou total das células – das ilhotas de Langerhans pancreáticas, resultando na incapacidade progressiva de produzir insulina e seu tratam

Externí odkaz: https://doaj.org/article/1efae352867d4816be732f0e3b4a91e3

Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study.

Autor: Kazakou P; Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. vkazakou@hotmail.com., Paschou SA; Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Mitropoulou M; Department of Endocrinology, Alexandra Hospital, Athens, Greece., Vasileiou V; Department of Endocrinology, Alexandra Hospital, Athens, Greece., Sarantopoulou V; Department of Endocrinology, Alexandra Hospital, Athens, Greece., Anastasiou E; Department of Endocrinology, Alexandra Hospital, Athens, Greece.

Publikováno v: Hormones (Athens, Greece) [Hormones (Athens)] 2023 Dec; Vol. 22 (4), pp. 695-701. Date of Electronic Publication: 2023 Sep 29.

Interaction of esomeprazole with insulin detemir and human albumin: A potential cause of hypoglycemia.

Autor: Hamdan II; Department of Pharmaceutical Sciences, School of Pharmacy, The University of Jordan, Amman, Jordan. Electronic address: I.Hamdan@ju.edu.jo., Farah DGH; Department of Pharmacy, Faculty of Pharmacy, Zarqa University, Zarqa, Jordan., Khalil EA; Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, The University of Jordan, Amman, Jordan., Mansour RSH; Faculty of Pharmacy, Philadelphia University, Amman, Jordan., Abdel-Halim H; Faculty of Pharmacy and Medical Sciences, University of Petra,Amman, Jordan.

Publikováno v: Biophysical chemistry [Biophys Chem] 2022 Jun; Vol. 285, pp. 106809. Date of Electronic Publication: 2022 Mar 28.

Optimization of pig models for translation of subcutaneous pharmacokinetics of therapeutic proteins: Liraglutide, insulin aspart and insulin detemir.

Autor: Pedersen KM; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Gradel AKJ; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv; Department of Veterinary and Animal Sciences, Section for Experimental Animal Models, University of Copenhagen. Electronic address: aqo@novonordisk.com., Ludvigsen TP; Translational Medicine, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Christoffersen BØ; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Fuglsang-Damgaard CA; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Bendtsen KM; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Madsen SH; Translational Medicine, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Manfé V; Global Research Technologies, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv., Refsgaard HHF; Global Drug Discovery, Novo Nordisk A/S, Novo Nordisk Park 1, DK-2760 Måløv.

Publikováno v: Translational research : the journal of laboratory and clinical medicine [Transl Res] 2022 Jan; Vol. 239, pp. 71-84. Date of Electronic Publication: 2021 Aug 21.